Status:
UNKNOWN
Azacytidine + HAG Regimen vs. Azacytidine for Elderly Patients With Newly Diagnosed Myeloid Malignancy
Lead Sponsor:
Shenzhen Second People's Hospital
Conditions:
Acute Myeloid Leukaemia; Myelodysplastic Syndromes;Chronic Myelomonocytic Leukemia
Eligibility:
All Genders
60-85 years
Phase:
PHASE4
Brief Summary
The primary objective is to explore the efficacy and safety of azacytidine and HAG regimen versus azacytidine for elderly patients with Newly Diagnosed MDS/AML/CMML in China. This is a post-marketing,...
Eligibility Criteria
Inclusion
- Age ≥ 60;
- Patients with newly diagnoised diseases including MDS/AML/CMML;
- The ECOG behavior status score is less than 3 points;
- Agree to sign informed consent
Exclusion
- Patients with a history of sever heart disease;
- Patients with severe organ dysfunction;
- Patients with other malignancies
- Patients who are allergic to the treatment of drug ingredients
Key Trial Info
Start Date :
September 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2023
Estimated Enrollment :
114 Patients enrolled
Trial Details
Trial ID
NCT03873311
Start Date
September 1 2019
End Date
June 1 2023
Last Update
March 15 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shenzhen Second People's Hospital
Shenzhen, Guangdong, China, 518035